[
    {
        "resourceType": "Procedure",
        "id": "proc-testa01-belimumab-01",
        "meta": {
            "profile": [
                "https://twcore.mohw.gov.tw/ig/twcore/StructureDefinition/Procedure-twcore"
            ]
        },
        "status": "completed",
        "category": {
            "coding": [
                {
                    "system": "http://snomed.info/sct",
                    "code": "18629005",
                    "display": "Administration of drug or medicament"
                }
            ],
            "text": "生物製劑治療"
        },
        "code": {
            "coding": [
                {
                    "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
                    "code": "1116635",
                    "display": "belimumab Injectable Product"
                },
                {
                    "system": "http://snomed.info/sct",
                    "code": "430127000",
                    "display": "Administration of biologic response modifier"
                }
            ],
            "text": "Belimumab 480mg IV infusion"
        },
        "subject": {
            "reference": "Patient/pt-testa-01",
            "display": "TESTA-01"
        },
        "encounter": {
            "reference": "Encounter/enc-testa01-01"
        },
        "performedDateTime": "2025-11-21",
        "performer": [
            {
                "actor": {
                    "reference": "Practitioner/prac-doc3311g",
                    "display": "陳光翰"
                }
            }
        ],
        "reasonReference": [
            {
                "reference": "Condition/cond-testa01-sle",
                "display": "Systemic lupus erythematosus"
            }
        ],
        "note": [
            {
                "text": "Benlysta 480mg IV infusion. Previous doses: 2024/07/23, 2024/08/30, 2024/09/29, 2024/10/26, 2024/11/30, 2025/01/05, 2025/06/15, 2025/07/18, 2025/08/19, 2025/09/16, 2025/10/17."
            }
        ]
    },
    {
        "resourceType": "Procedure",
        "id": "proc-testa01-belimumab-02",
        "meta": {
            "profile": [
                "https://twcore.mohw.gov.tw/ig/twcore/StructureDefinition/Procedure-twcore"
            ]
        },
        "status": "completed",
        "category": {
            "coding": [
                {
                    "system": "http://snomed.info/sct",
                    "code": "18629005",
                    "display": "Administration of drug or medicament"
                }
            ],
            "text": "生物製劑治療"
        },
        "code": {
            "coding": [
                {
                    "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
                    "code": "1116635",
                    "display": "belimumab Injectable Product"
                },
                {
                    "system": "http://snomed.info/sct",
                    "code": "430127000",
                    "display": "Administration of biologic response modifier"
                }
            ],
            "text": "Belimumab 480mg IV infusion"
        },
        "subject": {
            "reference": "Patient/pt-testa-01",
            "display": "TESTA-01"
        },
        "encounter": {
            "reference": "Encounter/enc-testa01-02"
        },
        "performedDateTime": "2026-01-02",
        "performer": [
            {
                "actor": {
                    "reference": "Practitioner/prac-doc3311g",
                    "display": "陳光翰"
                }
            }
        ],
        "reasonReference": [
            {
                "reference": "Condition/cond-testa01-sle",
                "display": "Systemic lupus erythematosus"
            }
        ],
        "note": [
            {
                "text": "Benlysta 480mg IV infusion. This is the 13th cycle."
            }
        ]
    },
    {
        "resourceType": "Procedure",
        "id": "proc-testa01-anifrolumab",
        "meta": {
            "profile": [
                "https://twcore.mohw.gov.tw/ig/twcore/StructureDefinition/Procedure-twcore"
            ]
        },
        "status": "stopped",
        "statusReason": {
            "coding": [
                {
                    "system": "http://snomed.info/sct",
                    "code": "58848006",
                    "display": "Lack of drug action"
                }
            ],
            "text": "Arthritis recurred despite treatment"
        },
        "category": {
            "coding": [
                {
                    "system": "http://snomed.info/sct",
                    "code": "18629005",
                    "display": "Administration of drug or medicament"
                }
            ],
            "text": "生物製劑治療"
        },
        "code": {
            "coding": [
                {
                    "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
                    "code": "2472872",
                    "display": "anifrolumab Injectable Product"
                }
            ],
            "text": "Anifrolumab IV infusion (self-paid)"
        },
        "subject": {
            "reference": "Patient/pt-testa-01",
            "display": "TESTA-01"
        },
        "performedPeriod": {
            "start": "2025-02-02",
            "end": "2025-05-18"
        },
        "performer": [
            {
                "actor": {
                    "reference": "Practitioner/prac-doc3311g",
                    "display": "陳光翰"
                }
            }
        ],
        "reasonReference": [
            {
                "reference": "Condition/cond-testa01-sle",
                "display": "Systemic lupus erythematosus"
            }
        ],
        "outcome": {
            "coding": [
                {
                    "system": "http://snomed.info/sct",
                    "code": "385671000",
                    "display": "Unsuccessful"
                }
            ],
            "text": "Arthritis recurred after 4 cycles"
        },
        "note": [
            {
                "text": "Received self-paid Anifrolumab on 2025/02/02, 2025/03/01, 2025/04/12, 2025/05/18 but symptoms seemed refractory. Switched back to Belimumab."
            }
        ]
    }
]